Zynerba Pharmaceuticals Inc expected to post a loss of 24 cents a share - Earnings Preview

Zynerba Pharmaceuticals

06/08/2021 12:46

* Zynerba Pharmaceuticals Inc  ZYNE.OQ   ZYNE.O  is expected
to show a no change in quarterly revenue when it reports
results on August 9 (estimated). 
​* Refinitiv's mean analyst estimate for Zynerba Pharmaceuticals
Inc is for a loss of 24 cents per share. For the same quarter
last year, the company reported a loss of 78 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Zynerba
Pharmaceuticals Inc is $8​, about 43.4% above​ its last closing
price of $4.53. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.25       -0.25      -0.20     Beat    19.8
 Dec. 31 2020  -0.29       -0.33      -0.33     Met     -0.4
 Sep. 30 2020  -0.43       -0.43      -0.31     Beat    28.3​
 Jun. 30 2020  -0.45       -0.45      -0.78     Missed  -74.4
 Mar.          -0.49​      -0.50      -0.53     Missed  -6.6​
 31​ 2020​                                              
 Dec. 31 2019  -0.50       -0.50      -0.46     Beat    8.5​
 Sep. 30 2019  -0.52       -0.52      -0.44     Beat    15.6
 Jun. 30 2019  -0.49       -0.50      -0.50     Met     -0.7
 This summary was machine generated August 6 at 11:46 GMT.  All
figures in US dollars unless otherwise stated